Lineage Cell Therapeutics
LCTX
105 hedge funds and large institutions have $73.1M invested in Lineage Cell Therapeutics in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 17 increasing their positions, 28 reducing their positions, and 11 closing their positions.
8,550% more call options, than puts
Call options by funds: $173K | Put options by funds: $2K
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
4% more funds holding
Funds holding: 101 → 105 (+4)
0.17% less ownership
Funds ownership: 38.31% → 38.14% (-0.17%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
29% less capital invested
Capital invested by funds: $103M → $73.1M (-$29.6M)
39% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$403K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$378K |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$225K |
| 4 |
RA
Raffles Associates
New York
|
+$220K |
| 5 |
Citigroup
New York
|
+$192K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$755K |
| 2 |
JP Morgan Chase
New York
|
-$305K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$224K |
| 4 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$191K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$102K |
LCTX Hedge Fund Activity: Q3 2022 in Review
105 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q3 2022, worth a combined $73.1M — down 29% from $103M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new LCTX positions and 11 closed out — a net gain of 5 holders — while 17 added to existing stakes and 28 trimmed.
The largest buyer was MAI Capital Management, adding an estimated $403K. The largest seller was Millennium Management, cutting an estimated $755K.
- 105 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q3 2022, up from 101 in Q2 2022.
- Funds reported $73.1M of Lineage Cell Therapeutics stock for Q3 2022, down 29% quarter-over-quarter.
- 16 funds opened new Lineage Cell Therapeutics positions in Q3 2022 and 11 closed out, a net change of +5 holders.
- The largest Lineage Cell Therapeutics buyer in Q3 2022 was MAI Capital Management, an estimated $403K added.
- The largest Lineage Cell Therapeutics seller in Q3 2022 was Millennium Management, an estimated $755K sold.
Based on aggregated 13F filings for Q3 2022.